Stay updated on Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.

Latest updates to the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page
- CheckyesterdayChange DetectedThe page’s footer/version indicator has been updated from Revision v3.5.2 to v3.5.3, reflecting a site release rather than a modification to the clinical trial information.SummaryDifference0.0%

- Check8 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check51 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check72 days agoChange DetectedThe change updates the page revision from v3.4.1 to v3.4.2, with no observed changes to study details or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1. This update does not affect study information or user-facing content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.